Compare TCRX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRX | SCLX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 55.1M |
| IPO Year | 2021 | N/A |
| Metric | TCRX | SCLX |
|---|---|---|
| Price | $0.79 | $6.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 888.0K | 106.3K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | $19.81 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.83 | $4.20 |
| 52 Week High | $2.57 | $34.27 |
| Indicator | TCRX | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 41.02 |
| Support Level | N/A | $5.72 |
| Resistance Level | $1.21 | $7.77 |
| Average True Range (ATR) | 0.10 | 1.02 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 0.81 | 4.02 |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.